since the initial approval of iclusig in europe in 2013, we have over 10 years of experience in treating patients with cml
Click on the short videos below to see how far we’ve come and learn why the experts think you should
consider switching eligible patients with CML* to ICLUSIG after one 2G TKI...
Jane Apperley
Centre for Haematology
Hammersmith Hospital
Imperial College London
London, UK
ICLUSIG has been with you since 2013,
proudly demonstrating fast, deep and durable responses
as seen in the long-term follow-up of the PACE study1,2
Jane Apperley Disclosures
Company/Organisation
Relationship(s)
Incyte, Novartis, Paladin Labs
Speaker
Incyte, Novartis
Advisory boards
BMS, Incyte, Novartis, Pfizer
Research funding
Gianantonio Rosti
IRCCS/SIRHHC Scientific Institute for Research, Hospitalization and Health Care ‘Dino Amadori’
Meldola (FC), Italy
The ELN CML Guidelines (2020) named
ICLUSIG as the preferred treatment in patients with resistance to a 2G
TKI without mutations, unless cardiovascular risk factors preclude its use3
Gianantonio Rosti Disclosures
Company/Organisation
Relationship(s)
Novartis, Pfizer, Incyte
Consultant
Novartis, BMS, Pfizer, Incyte
Research support
Novartis, BMS, Pfizer, Incyte
Speaker bureau
Novartis, Incyte
Advisory board
Jorge Cortes
Georgia Cancer Center
Augusta, GA, USA
Thanks to the recent response-based dosing study, OPTIC,
there’s now clear evidence to induce, reduce and maintain ICLUSIG to manage your patients4,5
Induce response with 45 mg orally, once daily; reduce dose to 15 mg orally, once daily, upon
achievement of ≤1% BCR::ABL1; maintain response with 15 mg orally, once daily.
Jorge Cortes Disclosures
Company/Organisation
Relationship(s)
BMS, Novartis, Pfizer, Takeda, Sun Pharma, Incyte
Consultant
BMS, Novartis, Pfizer, Takeda, Sun Pharma
Research support
ICLUSIG: COMMITMENT TO BUILDING PATIENTS' FUTURES
Adverse events should be reported. Reporting forms and information can be found at
www.hpra.ie.
Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number
1800-456-748.
You are now leaving the Incyte Iclusig website. This link will take you to a site that is not
owned or maintained by Incyte. Incyte is not responsible for the information contained on
third-party sites
You are now leaving the site www.iclusig.ie.
This link will take you to a site https://www.incyte.com, owned by Incyte Corporation and managed
by the company.